Skip to main content

Table 1 Clinicopathological features of advanced ovarian carcinomas with and without high-dose chemotherapy

From: Are there candidates for high-dose chemotherapy in ovarian carcinoma?

  CCA HDC p -value Odd or Hazard Ratio (95CI)
  N   N (%) N (%)   
    103 60   
Follow-up (median, months) 163   46.7 48.2 0.08***  
Median Age (years) 163   56,0 53,0 0 09***  
Age 163     0.73**** 1.15 [0.55-2.45]
   ≤50y 34 (33) 18 (30)   
   >50y 69 (67) 42 (70)   
OMS 117     0.17**** 0.35 [0.06-1.37]
   0-1 63 (81) 36 (92)   
   2-3 15 (19) 3 (8)   
FIGO 163     0.33**** 1.47 [0.63-3.39]
   IIIc 84 (82) 45 (75)   
   IV 19 (18) 15 (25)   
Histological subtype 163     0.62**** 0.82 [0.40-1.65]
   Serous 62 (60) 39 (65)   
   Others 41 (40) 21 (35)   
Grade 98     0.01**** 0.32 [0.12-0.81]
   1-2 19 (31) 21 (58)   
   3 43 (69) 15 (42)   
Cytoreductive surgery 160      
   Complete 56 (56) 40 (67) 0.24**** 0.64 [0.31-1.30]
   residual disease 44 (44) 20 (33)   
Clinical complete response* 161      
   Yes 63 (62) 50 (83) 0.007**** 0.33 [0.14-0.77]
   No 38 (38) 10 (17)   
CA-125** 149     0.66**** 0.75 [0.27-1.92]
   Normal 73 (80) 49 (85)   
   >Normal 18 (20) 9 (15)   
Time from end of initial CT to HDCT (median, months) 61   NA 2.8 NA NA
Median PFS (months)    18.1 20.1 0.09*****  
Median OS (months)    41.3 47.3 0.24*****  
  1. CCA, conventional chemotherapy alone; HDC, high-dose chemotherapy; N, number of cases with data available; 95CI, 95% confidence interval; OMS, performance status; NA, not asssessable; PFS, progression-free survival; OS, overall survival. *Clinical and radiological complete response after platinum and taxane-based chemotherapy; **, CA-125 rate after platinum and taxane-based chemotherapy; ***, T-test; ****, Fisher's exact test; *****, Log-rank test.